Skip to main content
All Posts By

admin

bionetworking bhcr logo

BioNetworking: Fermenting Innovation – Disruptive Science Tickets, Thu, Jun 29, 2017 at 3:00 PM

By News Archive

bionetworking-bhcr-logo

Event is for Post-Docs & Professional Scientists currently working in the Therapeutic Areas of:

  • Oncology
  • Respiratory, Inflammation & Autoimmunity •Cardiovascular & Metabolic Diseases •Infectious Diseases & Vaccines
  • Related scientific disciplines

Event will include music, lawn games, hors d’oeuvres, drinks.

MedImmune fully supports and abides by the PhRMA Code on Interactions with Healthcare Professionals. MedImmune cannot accommodate or pay for the cost of a spouse or other guest of a healthcare professional. As such, this event is open to invitees only. If you are a prescriber and/or a Federal, State, or Institution employee, you may be subject to laws, regulations, or rules which prohibit, limit, or require the public disclosure of gifts, meals, or items of value you may receive. We ask that you comply with any such laws, regulations, or rules that govern your receipt of gifts, meals, or items of value. Please bring your State License Number (SLN) and National Provider Identifier (NPI) to the event. These will be used for reporting purposes where required by state and federal law (OPEN Payments). You may look up your NPI and SLN at http://www.npinumberlookup.org/.

Read More
sr-one-logo

TP Therapeutics Closes $45M Series C Financing – Business Wire

By News Archive

sr-one-logo

TP Therapeutics, Inc., a clinical-stage biopharmaceutical company focusing on addressing oncology drug resistance, announced today that the company raised $45 million in a Series C financing round. The round was co-led by Lilly Asia Ventures (LAV), OrbiMed Advisors, LLC, and S.R. One, Limited, and joined by existing investors Cormorant Asset Management and SV Tech Ventures. In conjunction with the financing, Carl L. Gordon, Ph.D., CFA, General Partner at OrbiMed, Hongbo Lu, Ph.D., Partner at LAV, and Simeon J. George, M.D., Partner at S.R. One, joined the company’s Board of Directors.

Read More
Alexandria-Real-Estate-Equities-Logo

The #1 Real Estate Stock To Own Is Built On Trends – Alexandria Real Estate Equities (NYSE:ARE)

By News Archive

Alexandria-Real-Estate-Equities-Logo

Writing on trends, I frequently profile tech companies that use trends to outperform competitors. But using trends is not restricted to tech companies.

By following trends, since 1998 Alexandria Real Estate Equities has tripled the performance of the NASDAQ, quadrupled returns of the S&P 500, and quintupled the Russell 2000.  Alexandria has even outperformed technology stalwart Microsoft, and investment guru Berkshire Hathaway by 230%.

Read More
maryland-department-of-commerce-logo.png

Meet with AURP at the BIO International Convention

By Uncategorized

maryland-department-of-commerce-logo.png

BioParks 2017 is an opportunity to learn from biotech industry leaders, who share their data, experience, insights and vision. We will explore trends in life science research, funding resources, the marriage of life science and engineering and global partnership opportunities. Translating discoveries from the laboratory to the market has never been more important.

Read More

254th Edition – May 23, 2017

By BHI Weekly Newsletter Archives

maryland-department-of-commerce-logo.png

$12M in Biotechnology Investor Incentive Tax Credits Available

By News Archive

maryland-department-of-commerce-logo.png

Now is the time to make certain your company and investors are prepared to apply for the Maryland Biotechnology Investor Incentive Tax Credit (BIITC) program. Investors can receive income tax credits equal to 50%* of eligible investments in Qualified Maryland Biotechnology Companies (QMBC). $12M in funding is available for these credits during the FY18 fiscal year.

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.